Q-omics provides the consensus-scored ZRANB2-AS2 profile across patient tissues and cancer cell-line models. ZRANB2-AS2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ZRANB2-AS2 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZRANB2-AS2 RNA expression shows 19,178 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, THCA, and UVM as cancer lineages where ZRANB2-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZRANB2-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZRANB2-AS2 survival associations across molecular data types. ZRANB2-AS2 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZRANB2-AS2 RNA expression–survival associations across cancer types. High ZRANB2-AS2 expression shows unfavorable associations in BLCA and READ, but favorable associations in LUAD, KIRC, BRCA and ACC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify LUAD as the clearest survival context for ZRANB2-AS2 RNA expression.
This table summarizes ZRANB2-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZRANB2-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZRANB2-AS2 shows lower tumor expression in THCA, KICH, LUSC, KIRC, KIRP and UCEC. The THCA box plot shows higher ZRANB2-AS2 RNA expression in normal versus tumor tissue (log2 FC = −0.593, t-test p < 0.001).
This table shows molecular features associated with ZRANB2-AS2 in patient tissues and cancer cell lines. In patient samples, ZRANB2-AS2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
